


The Antibody Society presents:



Antibody Validation Webinar Series

WEBINAR 4: What is this antibody?

Moderator: **Dr. Simon Goodman**, The Antibody Society

Speakers: **Professor Anita Bandrowski**, University California San Diego and SciCrunch, and **Dr. Jan Voskuil**, Aeonian Biotech

First Webcast: December 5, 2019

[Now available On Demand](#)

Questions and Answers from the live Webcast on December 5, 2019

Question	Answer
Does the antibody society have a list of best practices for the antibody material data sheet?	SG response: Not yet.
Regarding a list of best practices for antibody material data sheets, is there a source for this? Would this be a good resource for users if The Antibody Society developed it?	AB response: Agreed!!!! I would be happy to help work on this. JV response: I don't think there is a list of best practices for antibody material data sheets. In fact, each provider has their own way about it and the customer just has to deal with it. When the scientist is not happy with the information provided, they should contact the provider or move on to the next one.
Why do manufacturers sell so few validated antibodies? What are their challenges?	AB response: I believe that one of the obstacles is financial. JV response: Each manufacturer/vendor has their own way to present their datasheet. Many run short of specifics. It is down to the scientist to make sure the correct antibody is identified by only buying when all expectations on the datasheet are met. SG response: Time and money. It is quick and cheap to produce a poorly characterized antibody. Maybe this is cynical... It is impossible for vendors to characterize every application and context that a future user might have. It remains in the hands of the scientist to ensure that a given antibody is fit-for-purpose in their specific indication. JV response: The best vendors will show some data to demonstrate the antibody is fit for a certain application. Some show comparisons between wildtype and KO. But the majority of catalogues leave lots of room for improvements. The scientist has to be vigilant.
Hi Anita, do we have a unified criteria to determine when an antibody is sufficiently different to deserve a new RRID?	AB response: The criteria we go by is to see if the product's conjugate status is different, and of course if the company sees fit to change the catalog number. One of the big questions is whether regular polyclonal antibodies from different batches should have the same catalog numbers. At some companies they get a new number, in others they maintain the same catalog number. This point would be very nice to standardize across the industry.

What is the necessary information to register an antibody with the RRID?	AB response: The basic information and validated uses should be made available to us. We then work to align the data to the data structure and make this available to authors at publication and to publishers' tools for validation.
How do we / where do we register our in-house / lab generated monoclonal antibody?	AB response: Just go to antibodyregistry.org/add you will be asked to log in, and to fill in a set of boxes. The curator will get back to you with additional questions if they cannot figure out some aspect.
Do you think that distributors will accept this identification system? Will this system reduce their sales?	JV response: I would have thought that the use of RRID would help bringing some trust and boost the sales. Not just for distributors, but for the entire market. AB response: I would second that.
Do you think aptamers could be used to replace some antibodies hard to produce?	SG & JV response: Aptamers are also costly to produce, and the validation issues remain similar to those with antibodies. Plus we have much wider experience of the difficulties involved with antibodies while aptamers are relatively untested in comparison.
When is the next episode??	SG response: Episode #5 is at 15:00 CET / 09:00 EST on 15th January 2020. Registration will open soon.